



Pentokey Organy (India) Limited

Date: 31st January, 2022

BSE Limited
P J Tower
Dalal Street, Fort
Mumbai, 400 001

Subject: Outcome of Board Meeting of Pentokey Organy (India) Limited held on 31st January, 2022

Reference: BSE Scrip Code: 524210

Madam/ Sir,

This is to inform you that pursuant to Regulation 30 & Regulation 33 of Securities Exchange Board of India (Listing Obligation and Disclosure requirement) Regulation 2015 "Listing regulation" and other applicable provisions, the Board of Directors of the company at its meeting held today have:

1. Approved the Unaudited Financial Results of the company for the quarter and nine months ended on 31st December, 2021;
2. Appointed Ms. Divya Desai as Company Secretary and Compliance Officer of the Company wef 31st January, 2022;

In view of the above, we hereby enclose the Un-audited Financial Results of Pentokey Organy (India) Limited for quarter and nine months ended 31st December, 2021 along with the Limited Review Report thereon.

The meeting of the Board of Directors of the Company commenced at 04:30 PM and concluded at 5.10 P.M.

This is for your information and records.

For PENTOKEY ORGANY (INDIA) LIMITED

P. Kejriwal

PURSHOTTAM KEJRIWAL
DIRECTOR
DIN: 02476745



CIN: L24116MH1986PLC041681

Reg. Office: 509, Western Edge I, Western Express Highway, Borivali(East), Mumbai- 400 066
Phone: +91-22-28545118 / 28545119 www.pentokey.com

PENTOKEY ORGANY (INDIA) LIMITED

CIN: L24116MH1986PLC041681

509, Western Edge I, Off Western Express Highway, Borivali East, Mumbai - 400 066.

Tel. No. (91-22) 28545118 email: investors@pentokey.com www.pentokey.com

UNAUDITED STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER/NINE MONTH ENDED 31ST DECEMBER, 2021

(' in Lakh)

Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Nine Month Ended	Nine Month Ended	Year Ended
	31.12.2021	31.12.2020	30.09.2021	31.12.2021	31.12.2020	31.03.2021
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I Revenue from Operations	-	-	-	-	-	0.09
II Other Income	6.72	6.97	5.43	15.65	23.77	29.89
III Total Revenue (I+II)	6.72	6.97	5.43	15.65	23.77	29.98
IV Expenses						
a) Purchase of Stock-in-trade / Cost of Materials Sold	-	-	-	-	-	-
b) Change in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
c) Employee benefits expenses	3.66	5.92	4.65	13.88	16.21	21.40
d) Depreciation and amortisation expense	0.12	0.06	0.13	0.36	0.14	0.26
e) Others Expenses	1.83	6.02	6.84	19.30	24.57	32.38
Total Expenses	5.60	12.00	11.62	33.54	40.92	54.04
V Profit / (Loss) before exceptional items and tax (III-IV)	1.11	(5.03)	(6.19)	(17.89)	(17.15)	(24.06)
VI Exceptional items - Profit / (Loss) on Sales of Property Plant & Equipments	-	-	-	-	-	-
VII Profit / (Loss) after exceptional items and tax (V+VI)	1.11	(5.03)	(6.19)	(17.89)	(17.15)	(24.06)
VIII Tax expense	-	-	-	-	-	-
Current Tax	-	-	-	-	-	-
IX Profit / (Loss) for the period from continuing operations (VII-VIII)	1.11	(5.03)	(6.19)	(17.89)	(17.15)	(24.06)
X Other Comprehensive Income	-	-	-	-	-	-
(i) Items that will not be reclassified to profit or loss	0.04	0.45	0.17	0.48	0.39	0.84
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
XI Total Comprehensive Income for the period (IX+ X)	1.15	(4.58)	(6.02)	(17.41)	(16.76)	(23.22)
XII Earnings per equity share (for continuing operations)						
1) Basic	0.01	(0.08)	(0.10)	(0.29)	(0.27)	(0.38)
2) Diluted	0.01	(0.08)	(0.10)	(0.29)	(0.27)	(0.38)

NOTES:

- The above results have been reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors in their meeting held on 31st January, 2022.
- The Statutory Auditors of the Company have carried out a limited Review of the above financial results.
- The above results pertain to "Pharma Segment" which is the only business segment of the Company.
- The above results have been prepared in accordance with the Company's (Indian Accounting Standards), Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 read with the rules thereunder and other recognised accounting practices and policies to the extent applicable.
- The figures for the previous year and corresponding period have been regrouped, rearranged or recasted wherever necessary to conform to current period's presentation.

For Pentokey Organy (India) Limited

Purshottam Kejriwal

Purshottam Kejriwal

Director

DIN : 02476745



Place : Mumbai

Date : 31st January, 2022



VERMA MEHTA & ASSOCIATES

Chartered Accountants

104, Creative Industries Premises, Sunder Nagar, Kalina, Sanatcruz (East) Mumbai 400098
Tel : 2666 6359 Fax : 6693 5131 E- Mail - vmaca92@gmail.com

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

To The Board of Directors

Pentokey Organy (India) Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Pentokey Organy (India) Limited ("the Company"), for the Quarter and Nine months ended December 31, 2021 ("the Statement"), together with the relevant notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015") read with SEBI circular dated July 5, 2016, which has been initialed by us for identification purposes. The Statement has been prepared in accordance with the recognition

and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.

3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data, and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Branch Office: Pune | Aurangabad | Ahmedabad | Vadodara | Mohali





VERMA MEHTA & ASSOCIATES

Chartered Accountants

104, Creative Industries Premises, Sunder Nagar, Kalina, Sanatcruz (East) Mumbai 400098
Tel : 2666 6359 Fax : 6693 5131 E- Mail - vmaca92@gmail.com

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015, read with SEBI circular dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement

For

M/s Verma Mehta & Associates

Chartered Accountants

Firm's Registration No: 112118W

CA Rohit Rahalkar

Partner

M.N. 139232

UDIN : 22139232AAAAAH5623

Place: Mumbai

Date: 31/01/2022

Branch Office: Pune | Aurangabad | Ahmedabad | Vadodara | Mohali

